alexa A New Model For Developing Intravitreal Formulations
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

9th Global Ophthalmology Summit
March 15-16, 2017 London, UK

Sahar Awwad
UCL School of Pharmacy, UK
Moorfields Eye Hospital, National Institute for Health Research (NIHR), UK
ScientificTracks Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.C1.057
Abstract
Damage to the posterior segments accounts for over 70% of the blind registrations in Europe. Treating many blinding conditions requires a medicine to be in the posterior cavity for a sufficient period of time. Inflammatory, angiogenic and fibrotic process in the retina causes tissue damage and vision loss. These biological processes are also major contributors to the failure of current treatments for these diseases. As the elderly segment of the population continues to grow, there is an urgent and unmet need to optimize the dose and duration of action of medicines in the posterior segment. The development of new therapeutic proteins is of particular importance since proteins tend to be fast-acting, selective and potent. New dosage forms and drug delivery systems (DDSs) are also being developed to augment the treatment of chronic blinding conditions and new DDSs are particularly needed for therapeutic proteins. During preclinical development, allometric modeling from in vivo models is not reliable due to: (i) the multitude of anatomical differences between animal and human eyes; and (ii) the immunological response of animals caused by the administration of a humanized protein. The formation of anti-drug antibodies (ADAs) in animals towards humanized proteins results in accelerated clearance rates making it impossible to evaluate prolonged dosage forms of new protein therapeutics. To prolong the release of a protein, a wide array of novel injectable formulations are being developed and reported in literature. The PK-eye in vitro model is a two-compartment, aqueous outflow model that has been shown to be particularly useful to estimate human protein PK profiles and to determine protein stability properties. Given the current design of the PK-Eye, there is now an opportunity to establish correlations with in vivo models using different injectable dosage forms. The PK-Eye model is used to evaluate new DDS and formulations that are being developed to prolong the release of a protein therapeutic. The PK-Eye is also being used to develop long- acting formulations and implants derived from non-protein low molecular weight (MW) actives. In contrast to proteins, low MW actives will generally clear by both (i) aqueous outflow and (ii) retinal permeation into the retina choroid sclera (RCS) pathway. Poorly soluble steroids are clinically used as suspensions and implants. TA (KenalogĀ®) displayed a residence time in the PK-Eye model that was 50% longer than what is observed in humans. Using permeation data to estimate retinal clearance pathways allow the determination of in-vitro in-vivo correlations (IVIVCs) during preclinical research. As a result, use of the PK-Eye can also estimate the human clearance times of long-acting implants of permeable drugs.
Biography

Sahar Awwad is a Post-doctoral Research Scientist at the University College London, School of Pharmacy, UK. She has recently completed her PhD under the supervision of Professor Steve Brocchini and Professor Sir Peng Tee Khaw. She obtained two scholarships for her PhD: (i) UCL Overseas Research Scholarship (ORS), and (ii) NIHR Biomedical Research in Ophthalmology at Moorfields Hospital. She has done her MSc in Drug Delivery from the University of London, School of Pharmacy (London, UK) and BPharm from Jamia Hamdard University (New Delhi, India). She has worked on various projects that have resulted in the development of a new in vitro model of ocular pharmaceutics along with a new strategy for extending the duration of action of therapeutic proteins in the eye. Her projects are widely based on drug delivery, ocular pharmaceutics, determination of IVIVCs for ocular PK and biodistribution properties, protein production, protein modification and protein characterization (surface plasmon resonance, stability and activity). She is the Co-founder of Optceutics Ltd., a new company utilizing the PK-Eye to develop new formulations.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords